[Coronary disease: benefits of aspirin. What dose for which disease?]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Thrombosis Research

Context:

• Coronary atherosclerosis frequently leads to thrombotic occlusion, a major cause of cardiovascular events.
• Aspirin is a well-established antiplatelet medication used in secondary cardiovascular disease prevention.
• Previous research has demonstrated aspirin's efficacy in reducing recurrent coronary events by approximately 25%.

Purpose:

• To review the established benefits of aspirin in secondary cardiovascular prevention.
• To determine the optimal dosage of aspirin for various pathological contexts, including acute myocardial infarction, post-infarction, unstable angina, and post-procedural settings.
• To analyze clinical trial data to identify effective aspirin dosing strategies.

Summary:

• Clinical trials indicate that daily aspirin doses between 160 mg and 300 mg are beneficial for secondary prevention of cardiovascular disease.
• Many studies have utilized a 300 mg/day dosage.
• The ISIS II study suggests that a 160 mg/day dose is most appropriate during the acute phase of myocardial infarction.

Impact:

• Provides evidence-based guidance on aspirin dosage for secondary cardiovascular prevention.
• Aims to optimize therapeutic strategies, potentially reducing the risk of recurrent thrombotic events.
• Highlights the importance of context-specific dosing for antiplatelet therapy.